ClinicalTrials.Veeva

Menu

Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis

N

Nanjing Medical University

Status

Completed

Conditions

Hidradenitis Suppurativa

Treatments

Drug: Mesalazine

Study type

Observational

Funder types

Other

Identifiers

NCT06568224
HouMaihua

Details and patient eligibility

About

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery. However, responses to treatments are variable and relapse is common, with no single agent being consistently effective.

Objective: To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa .

Methods: Investigators reported a series of cases of patients who received oral mesalazine(1g qid) for hidradenitis suppurativa in our institution between May 2020 and September 2023. A total of 27 patients, 22 in the mild to moderate group and 5 in the severe group, were included in this study.

Enrollment

27 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recurrent painful or suppurative lesions
  • Typical clinical manifestations: the distribution of apocrine sweat glands is deep in painful nodules, abscesses, sinuses, scars;

Exclusion criteria

  • Severe neurological and psychiatric diseases
  • Tumor diseases
  • Pregnant women in lactation period

Trial design

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems